page contents

Tag Archives: Therapeutics

Anchiano Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results Nasdaq:ANCN

(MENAFN – GlobeNewsWire – Nasdaq) itemprop=”articleBody”>– Successfully Completed $ 30.5 million U.S. Initial Public Offering in February 2019 – – Interim Analysis of the Codex Clinical Trial Expected in Fourth Quarter 2019 – CAMBRIDGE, Mass., March 12, 2019 (GLOBE NEWSWIRE) — Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (‘Anchiano’), a pivotal-stage biopharmaceutical company focused on the discovery and development of ...

Read More »

Aileron Therapeutics Inc (NASDAQ:ALRN) has coverage initiated with a Buy rating and $7.00 price target

Aileron Therapeutics Inc (NASDAQ:ALRN) has coverage initiated with a Buy rating and $ 7.00 price target Mar 11, 2019 (Market Exclusive via COMTEX) — Analyst Ratings For Aileron Therapeutics Inc (NASDAQ:ALRN) Today, HC Wainwright initiated coverage on Aileron Therapeutics Inc (NASDAQ:ALRN) with a Buy with a price target of $ 7.00. There are 1 Buy Ratings, no Strong Buy Ratings, ...

Read More »

Aileron Therapeutics Inc (NASDAQ:ALRN) has coverage initiated with a Buy rating and $7.00 price target

Aileron Therapeutics Inc (NASDAQ:ALRN) has coverage initiated with a Buy rating and $ 7.00 price target Mar 11, 2019 (Market Exclusive via COMTEX) — Analyst Ratings For Aileron Therapeutics Inc (NASDAQ:ALRN) Today, HC Wainwright initiated coverage on Aileron Therapeutics Inc (NASDAQ:ALRN) with a Buy with a price target of $ 7.00. There are 1 Buy Ratings, no Strong Buy Ratings, ...

Read More »

Aileron Therapeutics Inc (NASDAQ:ALRN) has coverage initiated with a Buy rating

Aileron Therapeutics Inc (NASDAQ:ALRN) has coverage initiated with a Buy rating Mar 11, 2019 (Market Exclusive via COMTEX) — Analyst Ratings For Aileron Therapeutics Inc (NASDAQ:ALRN) Today, HC Wainwright initiated coverage on Aileron Therapeutics Inc (NASDAQ:ALRN) with a Buy. There are 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock. The current consensus ...

Read More »

Audentes Therapeutics grants stock options to six new employees under Nasdaq Listing Rule 5635(c)(4)

Biotechnology company Audentes Therapeutics Inc (Nasdaq:BOLD) said on Friday that the board of directors’ compensation committee awarded equity awards to six newly appointed individuals in accordance with Nasdaq Listing Rule 5635(c)(4). On the grant date of 7 March 2019, the employees received, in the aggregate, options to purchase 14,600 common stock from the company. The options have an exercise price ...

Read More »

Audentes Therapeutics grants stock options to six new employees under Nasdaq Listing Rule 5635(c)(4)

Biotechnology company Audentes Therapeutics Inc (Nasdaq:BOLD) said on Friday that the board of directors’ compensation committee awarded equity awards to six newly appointed individuals in accordance with Nasdaq Listing Rule 5635(c)(4). On the grant date of 7 March 2019, the employees received, in the aggregate, options to purchase 14,600 common stock from the company. The options have an exercise price ...

Read More »

Audentes Therapeutics Inc (NASDAQ:BOLD) gets upgraded to Buy by Chardan Capital with a price target of $40.00

Audentes Therapeutics Inc (NASDAQ:BOLD) gets upgraded to Buy by Chardan Capital with a price target of $ 40.00 Feb 25, 2019 (Market Exclusive via COMTEX) — Analyst Ratings For Audentes Therapeutics Inc (NASDAQ:BOLD) Today, Audentes Therapeutics Inc (NASDAQ:BOLD) stock received an upgrade by Chardan Capital from Neutral to Buy with a price target of $ 40.00. There are 7 Buy ...

Read More »

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close